Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$13.17 +0.8%	$14.76	$10.60 ▼ $38.12	$1.39B	0.28	1.20 million shs	1.26 million shs
INDV Indivior	$13.95 +1.9%	$12.24	$7.33 ▼ $15.91	N/A	0.66	1.21 million shs	20.71 million shs
IRON Disc Medicine	$54.50 +0.7%	$48.47	$30.82 ▼ $68.73	$1.89B	0.73	339,865 shs	1.06 million shs
RAPP Rapport Therapeutics	$11.43 -3.2%	$10.94	$6.43 ▼ $29.74	$417.17M	N/A	166,384 shs	492,146 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	0.00%	-7.90%	-9.61%	-43.40%	-24.66%
INDV Indivior	0.00%	-0.43%	+12.41%	+45.92%	-15.40%
IRON Disc Medicine	0.00%	+5.60%	+16.28%	+4.09%	+25.55%
RAPP Rapport Therapeutics	0.00%	+4.67%	+34.31%	+13.73%	+1,142,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	3.4346 of 5 stars	4.4	3.0	1.9	3.3	0.0
INDV Indivior	1.8523 of 5 stars	1.6	3.0	2.6	1.7	1.9
IRON Disc Medicine	2.0053 of 5 stars	3.5	1.0	2.3	2.5	0.0
RAPP Rapport Therapeutics	2.2676 of 5 stars	3.5	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	202.03% Upside
INDV Indivior	3.25	Buy	$15.00	7.53% Upside
IRON Disc Medicine	3.09	Buy	$96.70	77.43% Upside
RAPP Rapport Therapeutics	3.00	Buy	$32.67	185.80% Upside

Current Analyst Ratings Breakdown

Latest RAPP, EWTX, IRON, and INDV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$28.00
4/8/2025	RAPP Rapport Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
INDV Indivior	$1.19B	N/A	$1.82 per share	7.66	($2.52) per share	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.16	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$3.45	N/A	N/A	N/A	N/A	-25.48%	-24.63%	8/14/2025 (Estimated)

Latest RAPP, EWTX, IRON, and INDV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	INDV Indivior	$0.25	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	20.99	20.99
INDV Indivior	N/A	0.88	0.72
IRON Disc Medicine	0.04	37.65	37.65
RAPP Rapport Therapeutics	N/A	31.01	31.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
INDV Indivior	60.33%
IRON Disc Medicine	83.70%
RAPP Rapport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
INDV Indivior	N/A
IRON Disc Medicine	4.24%
RAPP Rapport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A

RAPP, EWTX, IRON, and INDV Headlines

Recent News About These Companies

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)

...

June 12, 2025 | marketbeat.com

Stifel reiterates buy rating for Rapport Therapeutics stock

June 5, 2025 | uk.investing.com

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline

June 4, 2025 | nasdaq.com

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 16% - Still a Buy?

June 4, 2025 | marketbeat.com

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

June 2, 2025 | globenewswire.com

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025 | globenewswire.com

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 21, 2025 | globenewswire.com

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth

May 16, 2025 | finance.yahoo.com

Rapport Therapeutics Reports Q1 2025 Financial Results

May 9, 2025 | tipranks.com

Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments

May 8, 2025 | tipranks.com

Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.

May 8, 2025 | tipranks.com

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 8, 2025 | globenewswire.com

Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform

May 7, 2025 | finance.yahoo.com

Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%

May 3, 2025 | aaii.comA

Mise à disposition du rapport financier annuel 2024

April 30, 2025 | globenewswire.com

Why Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%

April 29, 2025 | aaii.comA

Rapport Therapeutics to Participate in Upcoming Investor Conferences

April 22, 2025 | globenewswire.com

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

April 18, 2025 | nytimes.com

Rapport Therapeutics initiated with an Outperform at Citizens JMP

April 9, 2025 | markets.businessinsider.com

Buy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS Disorders

April 9, 2025 | tipranks.com

JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation

April 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

RAPP, EWTX, IRON, and INDV Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$13.17 +0.11 (+0.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.95 -0.22 (-1.67%)

As of 06/27/2025 06:43 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Indivior NASDAQ:INDV

$13.95 +0.26 (+1.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.94 -0.01 (-0.11%)

As of 06/27/2025 06:18 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Disc Medicine NASDAQ:IRON

$54.50 +0.37 (+0.68%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$54.49 -0.01 (-0.02%)

As of 06/27/2025 05:59 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Rapport Therapeutics NASDAQ:RAPP

$11.43 -0.38 (-3.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.36 -0.06 (-0.57%)

As of 06/27/2025 04:34 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time